Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Cir- culation. 1998;98:734 41. 266. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957 66. 267. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/ IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895 903. 268. ten Berg JM, van t Hof AWJ, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment el- evation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol. 2010;55:2446 55. 269. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolim- us-eluting or uncoated stents for acute myocardial infarction: the MUL- TISTRATEGY randomized trial. JAMA. 2008;299:1788 99. 270. Akerblom A, James SK, Koutouzis M, et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol. 2010;56:470 5. O Gara et al 2013 ACCF/AHA STEMI Guideline e409 271. Ellis SG, Tendera M, de Belder MA, et al. 1-Year survival in a random- ized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv. 2009;2:909 16. 272. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary in- tervention of acute ST-segment elevation myocardial infarction: a meta- analysis. JAMA. 2004;292:362 6. 273. Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). 